Roth Capital Downgrades Vical (VICL) to Neutral

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Roth Capital Downgrades Vical (VICL) to Neutral

Vical Reports Top-Line Results From Phase 1/2 Trial of Therapeutic Genital Herpes Vaccine

June 22, 2015 4:10 PM EDT

The Primary Endpoint of Shedding Rate was not Met Conference Call and Webcast to be Held Today, June 22 at 5:00 pm ET

SAN DIEGO, June 22, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL) today announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients. The trial enrolled patients across seven U.S. sites and is evaluating two constructs: a monovalent (gD) vaccine and a bivalent (gD +... More